COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL

Protocol No
HOFFMANN-BO41932-TAPISTRY
Principal Investigator
Ben George
Phase
II
Summary
The purpose of this study is to compare the effects, good or bad, of targeted therapies or immunotherapy on patients who have solid tumors with specific genetic alterations or with a high number of mutations. Patients will be assigned to cohorts based on having a specific type of genetic alteration or having a high number of mutations in their tumor.
Description
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Participating Institutions
Froedtert Hospital
Status
SUSPENDED